Elekta adds Implant's brachytherapy TPS (treatment planning system) to prostrate cancer solutions:
This article was originally published in Clinica
Swedish group Elekta has rolled out the worldwide distribution of Implant Sciences' I-Plant brachytherapy treatment planning system (TPS) for prostate cancer, following an exclusive supply and distribution agreement between the two companies. Wakefield, Massachusetts-based Implant's current version of I-Plant TPS incorporates the treatment planning technology acquired from Rosses Medical Systems in fiscal 2005 and contains a new module that allows doctors to make two- and three-dimensional maps of stage, grade and location of cancer within the prostate gland.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.